News

Dave Inc. Reports Record Growth in Financial Results

Dave Inc. Reports Record Growth in Financial Results

Dave Inc. Achieves Remarkable Third Quarter Growth

Dave Inc. (NASDAQ: DAVE), one of the top neobanks in the United States, has reported impressive financial results for the third quarter, which has exceeded the company’s growth and profitability expectations once again. The latest results illustrate a continuing trend of accelerating year-over-year revenue growth, marking the fourth consecutive quarter in which the company has achieved this feat.

Outstanding Financial Highlights

In the third quarter, Dave saw its revenue surge by an impressive 41% year-over-year, amounting to $92.5 million. The net income also increased substantially, showing a remarkable recovery to $0.5 million from a loss of $12.1 million in the previous year. Additionally, the company's Adjusted EBITDA saw a remarkable leap, rising by $27.2 million to reach $24.7 million, showcasing the scalability and strength of its business model.

Growth Driven by Innovation

CEO Jason Wilk highlighted the contributions of their innovative product, CashAI, which has enabled improved credit performance thereby expanding variable margins by nearly 1,300 basis points year-over-year. Furthermore, there has been a notable increase in both Average Revenue Per User (ARPU) and Monthly Transacting Members (MTMs), with records being set for both metrics. This strong member growth is complemented by efficient customer acquisition costs that decreased by 14% to just $15.

New Strategic Partnership

In a significant move to diversify their commercial relationships, Dave Inc. recently entered into a non-binding letter of intent to form a strategic partnership with a reputable fintech sponsor bank. This partnership aims to boost the compliance and risk management aspect of their operations, thus enhancing the financing products offered to customers.

Impressive Key Performance Indicators

For the third quarter, several key metrics from the company displayed strong performance:

  • New Members rose by 4% to reach a total of 854,000, while Monthly Transacting Members increased by 23% to 2.4 million.
  • ExtraCash originations surged by 46% to $1.4 billion, reflecting growing trust among customers.
  • Dave Debit Card spending also showed a solid increase of 19%, totaling $407 million.
This reflects the company’s effective strategies and continued customer engagement efforts.

Financial Guidance for 2024

Looking ahead, Dave Inc. has announced an impressive revision of the revenue guidance for the full year of 2024, now expected to be between $340 million and $343 million, up from the previous guidance of $310 million to $325 million. The revised Adjusted EBITDA guidance also reflects a strategic enhancement, now projected to range between $71 million and $74 million for 2024.

Liquidity Position

The company reported a liquidity balance of $76.7 million as of the end of the quarter, though this has seen a slight decrease attributed to an increase in ExtraCash receivables. Nevertheless, Dave did not rely on its credit facility during the quarter, indicating a robust cash management strategy.

Future Prospects

The positive demand for ExtraCash, along with solid credit performance and low customer acquisition costs, positions the company favorably for achieving its ambitious forecasts for Q4 2024 and beyond. The management remains optimistic about its ability to deliver continued growth and value to its shareholders.

Frequently Asked Questions

What were the revenue figures for Dave Inc. in Q3 2024?

Dave Inc.'s revenue for Q3 2024 reached $92.5 million, showing a 41% increase year-over-year.

How has Dave's management viewed its performance in Q3 2024?

The management has expressed satisfaction, noting that they have once again exceeded growth and profitability expectations.

What strategic move has Dave Inc. made recently?

Dave Inc. has entered a non-binding letter of intent to form a partnership with a reputable fintech sponsor bank to diversify its commercial relationships.

What is the adjusted EBITDA guidance for 2024?

Dave Inc. has raised its Adjusted EBITDA guidance for 2024 to a range of $71 million to $74 million.

How is Dave's liquidity positioned as of the latest quarter-end?

As of the end of the most recent quarter, Dave Inc. held a liquidity position of $76.7 million, reflecting effective cash management despite a slight decrease from the previous period.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 173

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 123

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 203

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

dbt Labs Transforms Data Management with MetricFlow Open Source

Updated Category News Views 735

Embracing Open Source with MetricFlow In a groundbreaking move, dbt Labs recently announced its commitment to advancing trustworthy AI by open sourcing MetricFlow. This initiative represents a significant turning point in how organizations manage and utilize data in the era of artificial intelligence. The shift to an Apache 2.0 license not only safeguards the integrity of...

Continue Reading
EssilorLuxottica Achieves Euro 2 Billion Bond Issuance Success

Updated Category News Views 117

EssilorLuxottica's Successful Bond Issuance EssilorLuxottica has reached a noteworthy milestone by successfully issuing a Euro 2 billion bond at an attractive average rate of 2.99%. This strategic financial move highlights the company's strong position in the market and its appeal to investors. Details of the Bond Issuance The bond issuance features tenors of 4.5 years...

Continue Reading
Streamlined Home Selling Solutions Introduced in North Carolina

Updated Category News Views 292

Revolutionizing Home Selling in North Carolina Fair Cash Offers For Homes has recently launched its innovative service, ‘Sell Your House Fast North Carolina,’ designed to facilitate quick and efficient sales for homeowners. With the ever-changing real estate landscape, many individuals find themselves needing to sell their properties under various circumstances,...

Continue Reading
Ipsen Employee Admits to Insider Trading on Cancer Drug Deal

Updated Category News Views 268

Guilty Plea Tied to a Drugmaker’s Takeover Plans An employee at the French pharmaceutical company Ipsen has agreed to plead guilty to insider trading. The case, centered on trading ahead of a proposed acquisition, underscores the stakes around confidentiality in drug development and the pressures that test corporate governance. What Prosecutors Allege Dishant Gupta,...

Continue Reading
Oscar Health Achieves 52-Week Record with $23.45 Stock Price

Updated Category News Views 221

Oscar Health Achieves New Stock Performance Highs In a striking example of market resilience, Oscar Health, Inc. (OSCR) has reached an impressive 52-week high with its stock hitting $23.45. This achievement signifies a remarkable growth phase for the company, which has experienced an incredible one-year change of 288.51%. Investors have shown strong support for Oscar...

Continue Reading